News
Physician-perceived frailty and low life expectancy are the main reasons for warfarin discontinuation in elderly patients
News
Machaon Diagnostics has launched a same-day genetic testing service for patients that have been prescribed warfarin (Coumadin, from Bristol-Myers Squibb).
News
Compared with warfarin, dabigatran and rivaroxaban linked to lower risk of adverse renal outcomes
News
Apixaban is a direct oral anticoagulant that relies less on kidney excretion.
Drugs in the Pipeline
Bristol-Myers Squib and Pfizer announced results from their Phase 3 ARISTOTLE study of Eliquis (apixaban tablet) in patients with atrial fibrillation (AF) and at least one additional risk factor for stroke.
Drugs in the Pipeline
Johnson & Johnson Pharmaceutical Research & Development announced results from its Phase 3 study of rivaroxaban in non-valvular atrial fibrillation (AF) patients to reduce the risk of stroke and non-CNS systemic embolism.
News
A once daily oral dose of rivaroxaban (Xarelto) significantly lowers the risk of intracranial hemorrhage (ICH) in patients with atrial fibrillation (AF) at moderate to high risk of stroke.
Drug News
Patients with heart valve replacements have greater rates of thromboembolic and bleeding complications after treatment with dabigatran vs. warfarin.
News
After transcatheter aortic valve implantation (TAVI) there is no increased risk of bleeding or other adverse outcomes for those patients who have an indication for anticoagulant therapy.
News
For patients on warfarin with minor head trauma who have an initial negative computed tomography (CT) scan, 24-hour observation followed by an additional CT scan identifies the majority of cases of delayed bleeding.